MedTrace Logo

Efficacy and Mechanisms of Pharmacologic Treatment of Fecal Incontinence

NCT00727649 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2015-04-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate and compare treatment with fiber and loperamide for fecal incontinence.

Conditions

  • Fecal Incontinence

Interventions

DRUG

Psyllium powder

2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)

DRUG

Loperamide

1 capsule daily for 28 days (weekly adjusted dose)

Sponsors & Collaborators

Principal Investigators

  • Alayne D Markland, DO MSc · VA Medical Center, Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2013-10-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00727649 on ClinicalTrials.gov